Mark St Pierre, MD
Cardiovascular Disease · North Little Rock, ARNPI 1730130956
Payments from drug & device makers
Across 597 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Medtronic$1K
- Johnson & Johnson$762
- AstraZeneca$622
- Pfizer$563
- Merck$471
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 191 | $2,134 |
| Medtronic(2 entities) | 69 | $1,401 |
| Johnson & Johnson | 51 | $762 |
| AstraZeneca | 38 | $622 |
| Pfizer | 37 | $563 |
| Merck | 28 | $471 |
| Sanofi-aventis U.S. LLC | 27 | $454 |
| Amgen | 23 | $431 |
| Abiomed | 5 | $409 |
| Boehringer Ingelheim | 23 | $401 |
| Boston Scientific | 5 | $342 |
| Astellas Pharma US Inc | 5 | $233 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $192 |
| Actelion Pharmaceuticals US, Inc. | 10 | $180 |
| Irhythm Technologies, Inc. | 6 | $161 |
| Alnylam Pharmaceuticals Inc. | 9 | $161 |
| Abbott | 7 | $156 |
| E.r. Squibb & Sons, L.L.C. | 8 | $139 |
| Shockwave Medical, Inc | 1 | $121 |
| Amarin Pharma, Inc. | 7 | $117 |
| Baxter Healthcare | 5 | $91 |
| Bayer | 5 | $89 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $76 |
| Innovation Technologies Inc | 2 | $63 |
| Gilead | 4 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Cardiovascular Systems Inc. | 1 | $33 |
| Elutia, Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| GSK | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$10,061 in reported general payments places this provider in the 70th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in North Little Rock
- Thomas ConleyNorth Little Rock$12K
- Morris KelleyNorth Little Rock$10K
- Marvin AshfordNorth Little Rock$7K
- Jay GeoghaganNorth Little Rock$6K
- Charles CaldwellNorth Little Rock$5K
- Ian CawichLittle Rock$1.1M
- Christian Assad KottnerLittle Rock$670K
- Barry UretskyLittle Rock$609K
- Maximiliano ArroyoJonesboro$553K
- William RollefsonLittle Rock$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.